Patent registration (Development Code: SR-GT1) for stem cell gene therapy technology aimed at curing hereditary epidermolysis bullosa (Korea)

Section Heading

This report is a notice regarding the patent registration of the stem cell gene therapy technology SR-GT1 for the treatment of hereditary epidermolysis bullosa. Patents related to development code SR-GT1 have been registered in Korea, and the patentability and rights status of this technology are disclosed. The patent registration is positioned as a key milestone toward potential clinical application and could serve as material for future business development, partnerships, and fundraising. Since the filing region is Korea and the application number is not stated in the text, it is treated as unknown.

Section 2 Heading

As for future prospects, preparations toward clinical application are progressing steadily. Public information is limited, but technically there are indications of development of regenerative medicine products and initiatives geared toward international expansion. Given the application region is Korea, there may be plans to expand to other regions and pursue partnerships, making the progress of R&D and rights status a point of interest for investors.